Fournier Gangrene in a Patient Receiving Ixekizumab Therapy

We report a case of a 42-year-old man who developed Fournier gangrene while undergoing treatment of psoriatic arthritis with the interleukin-17 inhibitor ixekizumab (Taltz). There is growing use of biologics such as ixekizumab for symptom relief and control of various autoimmune diseases, including psoriatic arthritis. There is known increased risk for infection, both systemic and cutaneous, with the use of similar biologics. Specifically, ixekizumab has been reported to be associated with upper respiratory infections. However, there is little data on severe cutaneous infections. To our knowledge, we report the first case of Fournier gangrene as a potential adverse effect of ixekizumab use.